Arrowhead
Manufacturing · 560 employees
Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep, and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the ex
Funding history
- Funding Round — $500.0M — Aug 2024
Recent signals
- Apr 15, 2025: Arrowhead Pharmaceuticals Appoints Daniel Apel as Chief Financial Officer
- Nov 26, 2024: Arrowhead Pharmaceuticals and Sarepta Therapeutics Sign Global License and Collaboration Agreement for Multiple Clinical and Preclinical Programs
- Nov 01, 2024: Launched Arrowhead Pharmaceuticals Launches 'We'll Get There Soon' Campaign to Raise Awareness for Familial Chylomicronemia Syndrome.
- Aug 08, 2024: Raised $500.0M in Funding Round
- Aug 08, 2024: Arrowhead Pharmaceuticals Announces $500 Million Strategic Financing Facility with Sixth Street
See plans & pricing → Track Arrowhead’s funding, hiring, and signals — with verified contacts — on Fundz.